Literature DB >> 28262114

MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer.

Zhipin Liang1, Yaguang Xi2.   

Abstract

MicroRNAs (miRNAs) are a set of non-coding small RNA molecules that play a critical role in regulation of protein coding genes in cells. MiRNAs have been extensively studied as novel biomarkers, therapeutic targets, and new drugs in various human diseases. Breast cancer is a one of the leading tumor types significantly affecting women health worldwide. Over the past decade, a number of natural agents, such as paclitaxel and curcumin, have been applied for treatment and prevention of breast cancer due to their relatively low toxicity. However, the mechanisms of action have not been completely understood. Investigation on miRNAs is able to potentially provide a novel insight into better understanding the anticancer activities of these natural products. Given that a single miRNA can target multiple genes, theoretically, those genes involved in a certain phenotype can be clustered with one or a few miRNAs. Therefore, pleiotropic activities of natural agents should be interpreted by interactions between selected miRNAs and their targets. In this review, we summarize the latest publications related to the alterations of miRNAs by two natural agents (paclitaxel and curcumin) that are currently used in intervention of breast cancer, and conclude that the mechanism involving the regulation of miRNA expression is one of the keys to understand pleiotropic activities of natural agents.
Copyright © 2016 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cancer prevention; MicroRNA; Natural agents; Therapeutics

Mesh:

Substances:

Year:  2016        PMID: 28262114      PMCID: PMC5521805          DOI: 10.1016/S1875-5364(17)30012-2

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  53 in total

1.  Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer.

Authors:  Yaguang Xi; Reut Shalgi; Oystein Fodstad; Yitzhak Pilpel; Jingfang Ju
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

Review 2.  Cyclooxygenases 1 and 2.

Authors:  J R Vane; Y S Bakhle; R M Botting
Journal:  Annu Rev Pharmacol Toxicol       Date:  1998       Impact factor: 13.820

Review 3.  Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

Authors:  Debabrata Mukherjee
Journal:  Biochem Pharmacol       Date:  2002-03-01       Impact factor: 5.858

4.  Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.

Authors:  X S Chen; X Q Nie; C M Chen; J Y Wu; J Wu; J S Lu; Z M Shao; Z Z Shen; K W Shen
Journal:  Ann Oncol       Date:  2010-03-08       Impact factor: 32.976

5.  Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.

Authors:  Brian Koss; Jeffrey Morrison; Rhonda M Perciavalle; Harpreet Singh; Jerold E Rehg; Richard T Williams; Joseph T Opferman
Journal:  Blood       Date:  2013-07-23       Impact factor: 22.113

6.  miR181b is induced by the chemopreventive polyphenol curcumin and inhibits breast cancer metastasis via down-regulation of the inflammatory cytokines CXCL1 and -2.

Authors:  Emanuel Kronski; Micol E Fiori; Ottavia Barbieri; Simonetta Astigiano; Valentina Mirisola; Peter H Killian; Antonino Bruno; Arianna Pagani; Francesca Rovera; Ulrich Pfeffer; Christian P Sommerhoff; Douglas M Noonan; Andreas G Nerlich; Laura Fontana; Beatrice E Bachmeier
Journal:  Mol Oncol       Date:  2014-01-16       Impact factor: 6.603

7.  The ZNF304-integrin axis protects against anoikis in cancer.

Authors:  Burcu Aslan; Paloma Monroig; Ming-Chuan Hsu; Guillermo Armaiz Pena; Cristian Rodriguez-Aguayo; Vianey Gonzalez-Villasana; Rajesha Rupaimoole; Archana Sidalaghatta Nagaraja; Selanere Mangala; Hee-Dong Han; Erkan Yuca; Sherry Y Wu; Cristina Ivan; Tyler J Moss; Prahlad T Ram; Huamin Wang; Alexandra Gol-Chambers; Ozgur Ozkayar; Pinar Kanlikilicer; Enrique Fuentes-Mattei; Nermin Kahraman; Sunila Pradeep; Bulent Ozpolat; Susan Tucker; Mien-Chie Hung; Keith Baggerly; Geoffrey Bartholomeusz; George Calin; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Nat Commun       Date:  2015-06-17       Impact factor: 14.919

Review 8.  MicroRNAs: control and loss of control in human physiology and disease.

Authors:  Min Li; Christian Marin-Muller; Uddalak Bharadwaj; Kwong-Hon Chow; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

9.  Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.

Authors:  Hiroaki Kajiyama; Kiyosumi Shibata; Mikio Terauchi; Mamoru Yamashita; Kazuhiko Ino; Akihiro Nawa; Fumitaka Kikkawa
Journal:  Int J Oncol       Date:  2007-08       Impact factor: 5.650

Review 10.  miR-34: from bench to bedside.

Authors:  Massimiliano Agostini; Richard A Knight
Journal:  Oncotarget       Date:  2014-02-28
View more
  11 in total

1.  Role of miRNA-21/PTEN on the high glucose-induced EMT in human mesothelial peritoneal cells.

Authors:  Lina Yang; Yi Fan; Xiuli Zhang; Lili Gao; Jianfei Ma
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4.

Authors:  Gang Yu; Benli Jia; Yunsheng Cheng; Lianbang Zhou; Bo Qian; Zhining Liu; Yong Wang
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 3.  MicroRNAs are involved in the development and progression of gastric cancer.

Authors:  Xiaolin Liu; Ruixia Ma; Bin Yi; Adam I Riker; Yaguang Xi
Journal:  Acta Pharmacol Sin       Date:  2020-10-09       Impact factor: 7.169

4.  miR-371-5p suppresses the proliferative and migratory capacity of human nasopharyngeal carcinoma by targeting BCL2.

Authors:  Bifan Deng; Feiqun Su; Ruibin Xie; Weiguang Tang
Journal:  Oncol Lett       Date:  2018-04-12       Impact factor: 2.967

5.  Upregulated miR‑203a‑3p and its potential molecular mechanism in breast cancer: A study based on bioinformatics analyses and a comprehensive meta‑analysis.

Authors:  Kai-Teng Cai; Cai-Xia Feng; Jin-Che Zhao; Rong-Quan He; Jie Ma; Jin-Cai Zhong
Journal:  Mol Med Rep       Date:  2018-10-10       Impact factor: 2.952

6.  miR-155-5p Promotes Dorsal Root Ganglion Neuron Axonal Growth in an Inhibitory Microenvironment via the cAMP/PKA Pathway.

Authors:  Tianyi Wang; Bo Li; Zhijie Wang; Xin Yuan; Chuanjie Chen; Yanjun Zhang; Ziwei Xia; Xin Wang; Mei Yu; Wen Tao; Liang Zhang; Xu Wang; Zheng Zhang; Xiaoling Guo; Guangzhi Ning; Shiqing Feng; Xueming Chen
Journal:  Int J Biol Sci       Date:  2019-06-02       Impact factor: 6.580

7.  Evaluation of miR-34a Effect on CCND1 mRNA Level and Sensitization of Breast Cancer Cell Lines to Paclitaxel.

Authors:  Shiva Irani; Mahsa Paknejad; Masoud Soleimani; Soleimani Azam
Journal:  Iran Biomed J       Date:  2020-06-02

8.  Long Noncoding RNA CCAT2 Knockdown Suppresses Tumorous Progression by Sponging miR-424 in Epithelial Ovarian Cancer.

Authors:  Fu Hua; Chang-Hua Li; Xiao-Gang Chen; Xiao-Ping Liu
Journal:  Oncol Res       Date:  2017-05-21       Impact factor: 5.574

Review 9.  Regulatory Role of MicroRNAs in Muscle Atrophy during Exercise Intervention.

Authors:  Shufang Zhang; Ning Chen
Journal:  Int J Mol Sci       Date:  2018-01-30       Impact factor: 5.923

10.  miR-30b Promotes spinal cord sensory function recovery via the Sema3A/NRP-1/PlexinA1/RhoA/ROCK Pathway.

Authors:  Xin Wang; Bo Li; Zhijie Wang; Fengyan Wang; Jing Liang; Chuanjie Chen; Lei Zhao; Bo Zhou; Xiaoling Guo; Liqun Ren; Xin Yuan; Xueming Chen; Tianyi Wang
Journal:  J Cell Mol Med       Date:  2020-09-25       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.